Verenium (NASDAQ: VRNM) and Chemours (NYSE:CC) are both basic materials companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Dividends

Chemours pays an annual dividend of $0.12 per share and has a dividend yield of 0.2%. Verenium does not pay a dividend. Chemours pays out 8.3% of its earnings in the form of a dividend.

Analyst Ratings

This is a summary of current ratings for Verenium and Chemours, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verenium 0 0 0 0 N/A
Chemours 0 1 6 0 2.86

Chemours has a consensus price target of $57.86, indicating a potential upside of 9.60%. Given Chemours’ higher possible upside, analysts clearly believe Chemours is more favorable than Verenium.

Institutional and Insider Ownership

74.4% of Chemours shares are owned by institutional investors. 1.1% of Chemours shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Verenium and Chemours’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Verenium N/A N/A N/A ($1.56) -2.56
Chemours $5.40 billion 1.81 $7.00 million $1.45 36.41

Chemours has higher revenue and earnings than Verenium. Verenium is trading at a lower price-to-earnings ratio than Chemours, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Verenium and Chemours’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Verenium N/A N/A N/A
Chemours 4.86% 116.80% 8.10%

Summary

Chemours beats Verenium on 11 of the 12 factors compared between the two stocks.

Verenium Company Profile

Verenium Corporation (Verenium) is an industrial biotechnology company. The Company develops and commercializes enzymes for use in a range of industrial processes. It manufactures and markets its enzyme products in the fields of animal health and nutrition, grain processing, oilfield services and other industrial processes, such as pulp and paper and textiles. As of December 31, 2012, it marketed commercial enzyme products, either independently or in collaboration with its partners. In addition, it has developed a pipeline of enzyme product candidates. Its products are organized into four product lines: animal health and nutrition, grain processing, oilfield services and other industrial processes. As of December 31, 2012, it markets nine commercial enzyme products. In October 2013, BASF SE acquired 71% stake in the Company.

Chemours Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a North American provider of industrial chemicals used in gold production, oil and gas, water treatment and other industries. It delivers customized solutions with a range of industrial and specialty chemical products for markets, including plastics and coatings, refrigeration and air conditioning, industrial, mining and oil refining. Its products include titanium dioxide, refrigerants, industrial fluoropolymer resins and a portfolio of mining and industrial chemicals, including sodium cyanide. As of December 31, 2016, the Company operates 26 production facilities located in 10 countries.

Receive News & Ratings for Verenium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verenium and related companies with MarketBeat.com's FREE daily email newsletter.